Despite growing evidence supporting the efficacy and safety of the MiniMedTM 780G recommended settings (Glucose Target 100 mg/dL and Active Insulin Time 2 hours), their adoption in routine practice remains limited, mainly due to concerns about hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.